WebResults of Phase II studies show a 75% overall response rate in patients with relapsed or refractory Hodgkin’s lymphoma after stem cell transplant and an 86% response rate in patients with anaplastic large-cell lymphoma. 65,66. CD74 is another interesting target for non–CD20-expressing malignancies such as multiple myeloma. WebNov 23, 2024 · STRO-001 (Sutro Biopharma) is a CD74-directed, site-specific ADC developed for the treatment of multiple myeloma and lymphomas. Given broad …
Aberrant Expression of and Cell Death Induction by Engagement …
WebMar 1, 2024 · In NSCLC, the most common ROS1 fusion partner is CD74. Less common partners include SDC4, EZR, SLC34A2, TPM3, LIMA1, and MSN. ... and ALK-positive ALCL in 2024. In prior studies, common toxicities ... WebFunctionally, CD74 ligation induces cell death of ALCL cells. Furthermore, CD74 engagement enhances the cytotoxic effects of conventional chemotherapeutics in ALCL … market st grocery pittsburgh
CD74 is a novel transcription regulator PNAS
WebFunctionally, CD74 ligation induces cell death of ALCL cells. Furthermore, CD74 engagement enhances the cytotoxic effects of conventional chemotherapeutics in ALCL … WebCD74 has been reported to be expressed on myeloma cells in 86% (n = 22) patients [37]. It is normally expressed on B-cells and antigen presenting cells such as Langerhans cells in the skin [38,39]. CD74 is an attractive ADC ... relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. Jul; 2012 30(7):631–7 ... WebCD74, also known as IL, DHLAG, HLADG, Ia-GAMMA, or the invariant chain, is a B cell surface protein that is functionally important for the regulation of antigen presentation for immune responses. It is associated with class II major histocompatibility complex (MHC) and contains one thyroglobulin type-1 domain in its protein sequence. navisphere carrier account